{
    "clinical_study": {
        "@rank": "11669", 
        "acronym": "Neo-shorter", 
        "arm_group": [
            {
                "arm_group_label": "FEC3-D3", 
                "arm_group_type": "Active Comparator", 
                "description": "3 cycles of FEC followed by 3 cycles of Docetaxel\nFluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks\nDocetaxel 75 mg/m2, every 3 weeks"
            }, 
            {
                "arm_group_label": "AC4-D4", 
                "arm_group_type": "No Intervention", 
                "description": "4 cycles of Adriamycin plus Cyclophosphamide (AC) followed by 4 cycles of Docetaxel\nAdriamycin 60 mg/m2, every 3 weeks Cyclophosphamide 600 mg/m2, every 3 weeks\nDocetaxel 75 mg/m2, every 3 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Various regimens and schedule as neoadjuvant chemotherapy regimens were investigated and\n      sequential treatment of anthracyclines followed by taxanes, which has shown superior\n      pathologic complete respone (pCR) rate (NSABP-B27 study) is widely used until now.\n      Considering the proven efficacy and tolerable toxicity of 3 cycles of FEC followed by 3\n      cycles of Docetaxel (FEC3-D3) compared to FEC 6 cycles in adjuvant chemotherapy (PACS 01\n      trial), use of FEC3-D3 regimen in neoadjuvant setting will be feasible with acceptable\n      efficacy and further reduce the duration of neoadjuvant chemotherapy."
        }, 
        "brief_title": "Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer", 
        "completion_date": {
            "#text": "November 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Performance status 0 or 1\n\n          -  Clinically stage 2 or 3 with histologically proven lymph node involvement\n\n          -  Tumor or lymph node greater than 1.5 cm\n\n        Exclusion Criteria:\n\n          -  Pregnancy or lactation\n\n          -  Prior chemotherapy or radiotherapy for any malignancy\n\n          -  Documented history of cardiac disease contraindicating anthracyclines\n\n          -  Currently active infection"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "560", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02001506", 
            "org_study_id": "2012-0116"
        }, 
        "intervention": {
            "arm_group_label": "FEC3-D3", 
            "description": "Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks\nDocetaxel 75 mg/m2, every 3 weeks", 
            "intervention_name": "FEC3-D3", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Docetaxel", 
                "Doxorubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "breast cancer", 
            "neoadjuvant", 
            "different number of chemotherapy cycles"
        ], 
        "lastchanged_date": "December 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-746"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Sung-Bae Kim, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase III Trial of Neoadjuvant Chemotherapy With 3 Cycles of FEC Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Adriamycin Plus Cyclophosphamide Followed by 4 Cycles of Docetaxel in Node-positive Breast Cancer", 
        "overall_contact": {
            "email": "sbkim3@amc.seoul.kr", 
            "last_name": "Sung-Bae Kim, MD, PhD", 
            "phone": "+82-2-3010-3217"
        }, 
        "overall_contact_backup": {
            "email": "jeongeunkim@amc.seoul.kr", 
            "last_name": "Jeongeun Kim, MD, PhD", 
            "phone": "82-2-3010-3945"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Sung-Bae Kim, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "pathologic complete response (pCR) between two arms", 
            "safety_issue": "Yes", 
            "time_frame": "within the first 30 days (plus or minus 3 days) after surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02001506"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Sung-Bae Kim", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Correlation of pCR and Ki-67 expression at baseline and D14 tumor specimen\n3 year-disease free survival\nCorrelation of pCR and biomarkers such as Ki-67 expression", 
            "measure": "3 year-disease free survival between two arms", 
            "safety_issue": "Yes", 
            "time_frame": "3 year after surgery"
        }, 
        "source": "Asan Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}